More News! Pharma hemorrhages money, FDA on Interchangeability

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Susan Schmitz

  • Pharma is bracing for the impact of generics as a number of patents expire. Novartis stands to lose most on Sandostatin LAR, which has pulled in €1.5Bn in annual sales
  • The US Department of Justice has fined Shire $350M as threatened for “flagrant and systemic kickback activity”
  • Ethypharm (FR) has acquired Martindale Pharma (UK), which specialises in essential medicines for opioid addiction, emergency care and sterile injectables
  • Evotec is partnering with Asahi Kasei pharma to apply its integrated drug discovery platform to an ion channel target


  • Allergan and Hungarian pharma Gedeon Richter have encouraging results from a late-stage study of patients with symptomatic uterine fibroids
  • BMS is pulling out of the lung cancer combo race, effectively handing the space to Merck.
  • Lysogene’s LYS-GM101 for GM1 Gangliosidosis, a severe neurodegenerative disease, received Rare Pediatric Disease Designation to make it eligible for priority review by the FDA


  • The FDA has hammered out guidelines on interchangeability, one of the biggest hurdles for biosimilars to make it to market
  • Italian gene therapy company, Genenta, has recruited GSK vet Carlo Russo as CMO. Russo played a key role in the market approval of the first ex-vivo gene therapy, Strimvelis.

Trump or Raw Chicken?


Images from jdross75, Susan Schmitz, meunière, MoonAngelEyes /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.